ARTICLE
5 March 2025

ACI's 3rd Annual Forum On Advanced Therapeutics

HP
Hyman, Phelps, & McNamara

Contributor

Hyman, Phelps & McNamara, the largest FDA-focused law firm in the U.S., specializes in comprehensive legal solutions for companies regulated by the FDA and related agencies like the DEA, CMS, and USDA. The firm assists with regulatory compliance, product lifecycle management, marketing compliance, and due diligence, offering practical, responsive, and client-focused legal strategies. With extensive experience across the food, drug, and medical device sectors, their team supports businesses throughout the supply chain, providing tailored guidance to management, scientists, and compliance officers.

The American Conference Institute's 3rd Annual Forum on Advanced Therapeutics is scheduled to take place from March 19-20, 2025, at the Seaport Hotel in Boston, MA.
United States Food, Drugs, Healthcare, Life Sciences

The American Conference Institute's 3rd Annual Forum on Advanced Therapeutics is scheduled to take place from March 19-20, 2025, at the Seaport Hotel in Boston, MA. The conference will bring together industry leaders to explore evolving market trends, regulatory frameworks, and intellectual property strategies shaping the future of advanced therapeutics. From funding innovations and AI in drug discovery to navigating legal and compliance challenges, this conference will provide you with the opportunity to gain the insights you need to drive scientific advancements to global market success.

This collaborative endeavor drives forward the most groundbreaking developments in advanced therapeutics, marrying scientific discovery with strategic business and legal acumen for global impact. Attend to engage with leading industry thought leaders and legal pioneers who will illuminate the path from groundbreaking research to global market success.

Conference co-chairs include Derek Johnson (Managing Director and General Counsel, Portal Innovations) and Lulu Wang (Head of IP, Orna Therapeutics). Hyman, Phelps & McNamara, P.C.'s Charles Raver will speak during a panel discussion, titled "Preparing to Launch Preparing to Launch: Designing Your Commercialization Blueprint for Advanced Therapies and Companion Diagnostics," where the panelists will provide actionable insights into creating a streamlined pre-commercialization plan that aligns regulatory compliance with commercial objectives.

FDA Law Blog is a conference media partner. As such, we can offer our readers a special 10% discount. The discount code is: D10-999-FDA25. You can access the conference brochure and sign up for the event here. We look forward to seeing you at the conference.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More